Adoption of Sacubitril/Valsartan Among Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction: The Get With the Guidelines – Heart Failure Registry

By sjmartinez • November 29, 2022

Pierce JB, Li Z, Greiner M, Lippmann SJ, Hardy NC, Shen X, Stampehl M, Mentz RJ, Allen LA, Peterson PN, Fonarow GC, O'Brien EC, Greene SJ. Adoption of Sacubitril/Valsartan Among Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction: The Get With the Guidelines - Heart Failure Registry. Circ Heart Fail. 2022 Oct 31. doi: 10.1161/CIRCHEARTFAILURE.122.010176. Epub ahead of print. PMID: 36314141.

Tags: Cardiology/Epi, Publications

Demonstration and structural basis of a therapeutic DNA aptamer for SARS-CoV-2 spike protein detection

Liu Y, Wang K, Wang W, Kashyap S, Jih J, Imani A, Hsiai T, Zhou ZH. Demonstration and structural basis of a therapeutic DNA aptamer[...]

JNM Editors’ Choice Awards for 2024

Czernin J. JNM Editors' Choice Awards for 2024. J Nucl Med. 2025 Jun 12:jnumed.125.270522. doi: 10.2967/jnumed.125.270522. Epub ahead of print. PMID: 40506241.

Metabolic dysfunction-associated steatotic liver disease alters fatty acid profiles in the liver and adipose tissue

Palomurto S, Virtanen KA, Kärjä V, Schwab U, Kaminska D, Käkelä P, Pihlajamäki J, Männistö V. Metabolic dysfunction-associated steatotic liver disease alters fatty acid profiles[...]